Project Grant R01AG092949
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$4.5M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,754 to Nuravax, Inc. to evaluate the safety, tolerability, and immunogenicity of their adjuvanted preventive dual AB/tau vaccine, DUVAX, in healthy human volunteers. The award will fund a randomized, double-blind, placebo-controlled study to assess DUVAX's safety and ability to generate an immune response in participants aged 40-65. This research builds on preclinical studies...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...
This Project Grant award of $1,698,335.00 from the National Institute on Aging (part of the Aging Research program, CFDA 93.866) supports the development and preclinical testing of self-adjuvanting peptide nanofiber (PNF) vaccines targeting amyloid-beta and tau proteins for Alzheimer's disease and frontotemporal dementia. The grant aims to: 1) assess the toxicity and seeding capacity of PNFs bearing these epitopes, 2) characterize the antibody responses to AB and tau PNF vaccines, and 3) develop...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This $999,822 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Aeton Therapeutics Inc. supports the development of an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key objectives are to: Evaluate the effectiveness of Aeton's lead candidate, AT-01, in treating neural cells and organoids in vitro compared to another anti-tau antibody, HJ8.7. Determine the efficacy and safety of AT-01 versus HJ8.7 in a mouse model of tauopathy, while...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research at Virginia Commonwealth University (VCU) to investigate the effect of the trans-synaptic spread of pathogenic tau protein in the hippocampus and its impact on vulnerable neuron subtypes in Alzheimer's disease (AD). The $408,638 award, effective from August 1, 2024 to July 31, 2026, will involve the use of adeno-associated viral vector transfection, immunofluorescence, and...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Notre Dame provides $553,998.00 to develop a platform for discovering functional epitopes of the tau protein, which is implicated in several neurodegenerative diseases. The key objectives are to: 1) synthesize a library of conformationally-constrained macrocyclic peptides that mimic pathological tau folds, 2) evaluate the ability of these "mini-tau" peptides to seed...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to discover and characterize novel tau proteoforms in blood that can differentiate Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) from healthy controls. The $3,687,575 award to the Trustees of Indiana University, Indianapolis, will leverage samples from completed clinical trials of tau immunotherapies to overcome sensitivity limitations and identify potential biomarkers for...